TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with any type of non-small cell lung cancer who are undergoing medical treatment, including surgery, radiation and / or chemotherapy.~Exclusion Criteria:~* Metastasis to the brain, problems during surgery leading to myocardial infarction or hemorrhage, cerebral infarction or hemorrhage, respiratory failure, non-healing surgical wound.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (yoga) (Type: EXPERIMENTAL): Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
- Arm II (emotional support group therapy) (Type: ACTIVE_COMPARATOR): Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* full-term singleton pregnant women~* American society of anesthesiologist I or II,~* scheduled for elective cesarean delivery~Exclusion Criteria:~* Patients with uncontrolled cardiac morbidities (patients with tight valvular lesion, impaired contractility with ejection fraction \< 50%, heart block, and arrhythmias),~* hypertensive disorders of pregnancy,~* peripartum bleeding,~* coagulation disorders (patients with INR \>1.4 and or platelet count \< 80000 /dL)~* any contraindication to regional anesthesia,~* baseline systolic blood pressure (SBP) \< 100 mmHg will be excluded from the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- epinephrine 0.03 mcg (Type: ACTIVE_COMPARATOR): None
- epinephrine 0.05 mcg (Type: ACTIVE_COMPARATOR): None
- epinephrine 0.07 mcg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject meets all of the following criteria:~* Scheduled for an outpatient ERCP to diagnose a potential biliary disorder (such as an indeterminate biliary stricture)~* Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities)~* Age 18 to 100 years~* Willing and able to sign informed consent~Exclusion Criteria:~* Subjects with known allergy or negative reaction to any components of the study drug (list these)~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive~* Anything that, in the opinion of the investigator, would place the individual at increased risk or preclude the individual's full compliance with or completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Dimer Application with SFE imaging (Type: EXPERIMENTAL): Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Modified Constrained - Induced Movement Therapy Compared to Intensive Bimanual Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Upper extremity hemiparesis~* Between 2 and 16 weeks post-stroke~* At least 10º active extension of the wrist and at least 10º active extension of the thumb and at least 2 additional fingers~Exclusion Criteria:~* Cognitive problems, Mini Mental Status \< 24~* Excessive pain in the paretic extremity~* Major medical problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Modified Constraint-Induced Movement therapy (Type: EXPERIMENTAL): Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
- 2.Task-specific bimanual training (Type: EXPERIMENTAL): Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18~2. Histologically or pathologically proven non-small cell lung cancer (NSCLC)~3. Leptomeningeal carcinomatosis confirmed by CSF cytology~4. A patients with EGFR mutation (including exon 19 deletion, L858R)~5. ECOG performance status 0-3~6. Expected life time more than at least 4 weeks~7. A patients who signed the informed consent prior to the participation in the study~8. Chemotherapy-naïve patient is eligible~9. Previous EGFR TKI is allowed if this drug was not specifically used for CNS metastases~Exclusion Criteria:~1. A pregnant or lactating patient~2. A patient of childbearing potential without being tested for pregnancy at baseline or with a positive test. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)~3. A man or woman of childbearing potential without the willingness to use a contraceptive measures during the study~4. A patient with history of another malignant disease within past 3 years, except curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer~5. A patient with active interstitial lung disease, except simple lymphangitic lung metastasis~6. A patient with history of allergic reaction to gefitinib or erlotinib~7. The following laboratory test results:~   * Number of absolute neutrophils counts (ANC) \< 1.0ⅹ109/L~  * Number of platelets \< 50 ⅹ109/L~  * AST, ALT \> 2.5 ⅹupper limit of normal~  * Total bilirubin \> 1.5 ⅹupper limit of normal~  * Serum creatinine \> 1.5 ⅹupper limit of normal~8. A patient with serious disease as followings~   * Uncontrolled cardiac arrhythmia~  * History of myocardial infarction within 6 months prior to the initiation of study~  * Neurological or psychiatric disorder including dementia or uncontrolled seizure~9. A patient who refused to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib 150mg/day (if no negative conversion --\> increment to 250mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Support Intervention on Newly Licensed Nurses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly Licensed Nurses,~* ages 19-37 years,~* proficient in English,~* working in an acute care facility as a RN during the first year of hire,~* have a working personal Smartphone,~* have the ability to send and receive text messages,~* have an active and working personal email account, and~* be willing to participate for six weeks,~* complete a demographic survey before the study, survey instruments at 3 weeks, 6 weeks, and at the conclusion of the study~* agree to not use or carry their Smartphone while performing direct patient care and~* assume any data charges for text messages, if incurred.~Exclusion Criteria:~* Newly Licensed Nurses who have worked in the role of a RN on another floor or~* NLNs who have worked as an RN at another organization, or~* NLNs not 19-37 years of age.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): The control group will receive medical facts and are not meant to support newly licensed nurses and are not known to affect stress, resilience, perceived social support, or Intention To Leave one's job.
- Experimental Group (Type: EXPERIMENTAL): Texts sent to the experimental group will be based on nurturant support messages and are intended to decrease stress, Intention To Leave, increase resilience, and perceived sense of support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Augmentation Cystoplasty Using an Autologous Neo-Bladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* subjects with neurogenic bladders secondary to myleodysplasia~Exclusion Criteria:~* prior augment procedures~* recent urologic surgery~* requires concomitant urologic intervention

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Neo-bladder construction (Type: EXPERIMENTAL): Surgical implantation of autologous neo-bladder construct

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of SU 011248 in Head And Neck Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation~* Recurrence must be confirmed by anatomopathology (cytology or biopsy)~* At least one measurable lesion by MRI or CT-scan~* Failed or relapsing after first line chemotherapy including a platinum\* or a taxane-based chemotherapy regimen~* Patients ineligible for chemotherapy could be included in first line~* ECOG performance status 0 -2, in stable medical condition~* Patients must be able to swallow tablets~* Patients must have an expected survival of at least 3 months~* Paraffin-embedded tumor tissue available for immunohistochemistry~* Patients must be over 18 years old and must be able to give written informed consent~* Women of child-bearing age must have a negative pregnancy test~* Female patients of child-bearing age must use effective contraception until 3 months have elapsed after the last injection~* Patients must have normal organ function~* For patients with local recurrence and easily accessible tumors, acceptance of iterative biopsies to store tumor samples (Formaldehyde for immunochemistry, RNA later)~* Acceptance of giving 20 ml of blood for eventual pharmacogenomic analysis~* Acceptance of giving two plasma samples (3ml) at baseline and after 4 weeks of treatment with SU011248~* Signed informed consent prior to beginning protocol specific procedure~Exclusion Criteria:~* Non-squamous head and neck cancer~* Nasopharynx cancer~* Brain metastases~* More than two lines of chemotherapy for palliative treatment (except if chemotherapy was given as a part of a multimodal treatment given with a curative intent)~* Surgery or irradiation or investigational drugs within 4 weeks before study inclusion~* Other uncontrolled illnesses (active infections requiring antibiotics, bleeding disorders, ...)~* Active uncontrolled coronary disease or cardiac insufficiency (Ejection fraction below 40%)~* Previous malignancy, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Other concomitant anticancer therapies~* Previous treatment with anti-VEGF, PDGF, or kit therapies. EGFR therapy is not an exclusion criteria.~* Organic brain syndrome or significant psychiatric abnormality that would preclude participation in the full protocol and follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): patients will receive SU011248 in monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18-80)~* who are admitted to the ICU for hematemesis, or coffee ground emesis~Exclusion Criteria:~1. Patients younger than 18 yrs old or older than 80 yrs~2. Patients who refuse to consent to be in our study~3. Pregnant patients~4. Prior use of prokinetics in the last 48 hours~5. History of cardiac arrhythmia~6. Allergy to erythromycin or metoclopromide~7. Patients with QT prolongation (query 7)~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Erythromycin (Type: EXPERIMENTAL): Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
- Metoclopromide (Type: EXPERIMENTAL): Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
- Control (Type: NO_INTERVENTION): no medications will be given prior to endoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intracoronary Abciximab With Clearway Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients (men or women) at least 18 years of age~2. STEMI: Presenting with ischemic chest discomfort \> 20 minutes and \<6 hours of duration suggestive of acute myocardial infarction AND ST elevation \> 1 mm (\> 0.1 mV) in two contiguous limb leads OR \> 2 mm (\> 0.2 mV) in two contiguous precordial leads~3. Must have signed the informed consent form prior to performance of study-related procedures~4. Native dominant and proximal culprit vessel 2.5 mm in diameter~5. Angiographically identifiable thrombus (presence of a filling defect within the coronary lumen surrounded by contrast medium observed in multiple projections, without calcium within the filling defect, or persistence of contrast medium within the coronary lumen)~6. Pre-PCI Thrombus score (TS) ≥ 2 (angiographically apparent thrombus that is \> ½ the vessel diameter)~7. Pre-PCI TIMI flow grade of 0-2~Exclusion Criteria:~1. Previous PCI of the IRA~2. Previous myocardial infarction or coronary artery bypass grafting~3. Cardiogenic shock~4. Three vessel disease~5. Left main disease~6. Severe valvular heart disease~7. Rescue PCI (PCI following fibrinolytic administration)~8. Facilitated PCI (PCI following fibrinolytic or GP IIb/IIIa inhibition)~9. Contraindication to GP IIb/IIIa inhibitors such as excess bleeding risk or thrombocytopenia~10. Current participation in another investigational trial~11. Exclusion criteria for the MRI imaging include implanted pacemakers, defibrillators, or metallic intracranial implants, severe claustrophobia, BMI \> 35 kg/m², atrial fibrillation or known not well controlled extrasystoles (bad images), or allergy to gadolinium-DTPA~12. Enrolment of patients with an estimated glomerular filtration rate \< 30 ml/min/1.73 m2 should be carefully evaluated considering the gadolinium chelate-associated risk of nephrogenic systemic fibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Abciximab (Type: EXPERIMENTAL): IC bolus of abciximab
- IV Abciximab (Type: ACTIVE_COMPARATOR): IV abciximab + infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patient with CRPC and experiencing disease progression as defined by PCWG2~* ECOG 0-2~* Must continue gonadal castrative therapy~* Has completed antiandrogen withdrawal ≥ 6 weeks prior to registration~* Metastatic disease documented by imaging~* Patient is planned for treatment with docetaxel or abiraterone~* If treated with bisphosphonates or denosumab, has been on these for ≥ 6 weeks.~* Must provide written informed consent~Exclusion Criteria:~* Prior history of invasive malignant disease unless disease free for at least 5 years, with the exception of non-melanoma skin cancer~* Planned for any concurrent anticancer treatment oher than docetaxel or abiraterone~* Prior radiotherapy or surgery within 4 weeks of start of docetaxel or abiraterone~* Inability to comply with the imaging requirements (eg. inability to lie supine for one hour)~* Allergy to MRI contrast agent or PET tracer to be used as part of the imaging~* Sickle cell disease or other hemoglobinopathies~* Insufficient renal function (eGFR ≤ 30 mL/min)~* Known residual bladder volume \> 150 cc~* Hip prosthesis or intrabdominal vascular grafting~* Contraindication to CT contrast~* Contraindication to MRI as per institutional policy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: OTHER): Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a \[F-18\]-FCH PET scan with full body MRI scan
- Abiraterone (Type: OTHER): Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a \[F-18\]-FCH PET scan with full body MRI scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premature infants \<1500 g~* Mother consenting to provide breast milk or use of donor breast milk~Exclusion Criteria:~* Infants with major congenital malformations~* Infants with medical conditions precluding them from having breast milk~* Mothers with medical conditions that preclude them form providing breast milk~* Insufficient breast milk supply~* Refusal of donor breast milk~* Mother is non-English speaking

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Control group (standard fortification) (Type: NO_INTERVENTION): Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines.
- Intervention group (targeted fortification) (Type: EXPERIMENTAL): Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues